Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27,767,902
-
Total 13F shares
-
19,411,772
-
Share change
-
+86,512
-
Total reported value
-
$955,770,887
-
Put/Call ratio
-
453%
-
Price per share
-
$49.32
-
Number of holders
-
144
-
Value change
-
+$8,025,561
-
Number of buys
-
64
-
Number of sells
-
70
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q1 2021
As of 31 Mar 2021,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
144 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,411,772 shares.
The largest 10 holders included
BlackRock Inc., Farallon Capital Management, L.L.C., VANGUARD GROUP INC, ARMISTICE CAPITAL, LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, PRICE T ROWE ASSOCIATES INC /MD/, Krensavage Asset Management, LLC, NORTHERN TRUST CORP, and DIMENSIONAL FUND ADVISORS LP.
This page lists
144
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.